Tania Crombet, Director of Clinical Research, Havana-based Molecular Immunology Center Production facilities at Cuba’s Molecular Immunology Center Its time to take the moonshot together against cancer. Oakland, CA (PRWEB) November 02, 2016 MEDICC Review journal features an exclusive interview with the Director of Clinical Research of Cubas Molecular Immunology Center, home to innovative cancer vaccines and therapies, including CIMAvax for non-small cell lung cancer, recently cleared for U.S. clinical trials. http://cameronhenryplanet.denaliinstitute.org/2016/09/29/some-practical-concepts-for-painless-secrets-for-medicineThe Center is partner to Roswell Park Cancer Institute (Buffalo, NY) in a new joint venture just approved by Washington, to test CIMAvax and other novel Cuban therapies against cancer, a leading cause of death in both countries. Its time to take the moonshot together against cancer, said Gail Reed, MEDICC Review Executive Editor. Thats why were seeing the green light for this joint venture, and also the recent agreement signed in Havana by Health and Human Services Secretary Sylvia Mathews Burwell. In this new political era, we are hopeful that our scientists can collaborate in tangible ways to fight cancer in both countries and around the world. Read the complete interview with Dr. Tania Crombet , Director of Clinical Research, Molecular Immunology Center, Havana Science, Passion & Compassion vs. Cancer. Covering the latest in the field of Cuban health and medicine, the new issue of MEDICC Review also features: Tackling Gender Violence in Primary Care MEDICC Review is the first peer-reviewed journal in English dedicated to publishing original manuscripts by Cuban health and related professionals on topics of medical research, population health, and policies and practice of health in Cuba. The journal also publishes international authors on subjects related to health equity and vulnerable populations.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2016/11/prweb13812609.htm